Carna Biosciences, Inc. revised consolidated earnings guidance for the fiscal year ending December 31, 2022. For the year, the company expected net sales to be JPY 1,186 million as compared to previous guidance of JPY 1,127 million, Operating loss to be JPY 1,672 million as compared to previous guidance of JPY 1,730 million, Loss attributable to owners of parent to be JPY 1,740 million as compared to previous guidance of JPY 1,799 million and Net loss per share to be JPY 128.46 as compared to previous guidance of JPY 133.56.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
436 JPY | +0.23% | +1.40% | -16.48% |
1st Jan change | Capi. | |
---|---|---|
-16.48% | 48.11M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- 4572 Stock
- News Carna Biosciences, Inc.
- Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022